PL408251A1 - Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A - Google Patents
Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10AInfo
- Publication number
- PL408251A1 PL408251A1 PL408251A PL40825114A PL408251A1 PL 408251 A1 PL408251 A1 PL 408251A1 PL 408251 A PL408251 A PL 408251A PL 40825114 A PL40825114 A PL 40825114A PL 408251 A1 PL408251 A1 PL 408251A1
- Authority
- PL
- Poland
- Prior art keywords
- phosphodiesterase
- triazole
- inhibitors
- condensed derivatives
- compound
- Prior art date
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title 1
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Lubricants (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| PT15730261T PT3145930T (pt) | 2014-05-19 | 2015-05-14 | Derivados de triazole fundidos como inibidores da fosfodiesterase 10a |
| DK15730261.3T DK3145930T3 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
| PL15730261T PL3145930T3 (pl) | 2014-05-19 | 2015-05-14 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| AU2015263013A AU2015263013B2 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
| CN201580025963.XA CN106459060B (zh) | 2014-05-19 | 2015-05-14 | 作为磷酸二酯酶10a抑制剂的稠合的三唑衍生物 |
| KR1020167035389A KR102404650B1 (ko) | 2014-05-19 | 2015-05-14 | 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체 |
| PCT/IB2015/053549 WO2015177688A1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
| SI201530382T SI3145930T1 (sl) | 2014-05-19 | 2015-05-14 | Kondenzirani triazolni derivati kot inhibitorji fosfodiesteraze 10A |
| HUE15730261A HUE039847T2 (hu) | 2014-05-19 | 2015-05-14 | Kondenzált triazolszármazékok foszfodiészteráz 10A inhibitorként |
| CA2946258A CA2946258C (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
| MX2016015180A MX367647B (es) | 2014-05-19 | 2015-05-14 | Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a. |
| ES15730261.3T ES2688084T3 (es) | 2014-05-19 | 2015-05-14 | Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A |
| JP2016568435A JP6455947B2 (ja) | 2014-05-19 | 2015-05-14 | ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体 |
| HRP20181027TT HRP20181027T1 (hr) | 2014-05-19 | 2015-05-14 | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a |
| EA201692264A EA030330B9 (ru) | 2014-05-19 | 2015-05-14 | Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a |
| US15/311,698 US10138245B2 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
| EP15730261.3A EP3145930B1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL408251A1 true PL408251A1 (pl) | 2015-11-23 |
Family
ID=53434395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| PL15730261T PL3145930T3 (pl) | 2014-05-19 | 2015-05-14 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15730261T PL3145930T3 (pl) | 2014-05-19 | 2015-05-14 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10138245B2 (enExample) |
| EP (1) | EP3145930B1 (enExample) |
| JP (1) | JP6455947B2 (enExample) |
| KR (1) | KR102404650B1 (enExample) |
| CN (1) | CN106459060B (enExample) |
| AU (1) | AU2015263013B2 (enExample) |
| CA (1) | CA2946258C (enExample) |
| DK (1) | DK3145930T3 (enExample) |
| EA (1) | EA030330B9 (enExample) |
| ES (1) | ES2688084T3 (enExample) |
| HR (1) | HRP20181027T1 (enExample) |
| HU (1) | HUE039847T2 (enExample) |
| MX (1) | MX367647B (enExample) |
| PL (2) | PL408251A1 (enExample) |
| PT (1) | PT3145930T (enExample) |
| SI (1) | SI3145930T1 (enExample) |
| WO (1) | WO2015177688A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017007301A1 (en) * | 2015-07-06 | 2017-01-12 | Universiti Sains Malaysia | Compound and method for inhibiting sirtuin activities |
| KR102587382B1 (ko) * | 2016-04-29 | 2023-10-12 | 솔루스첨단소재 주식회사 | 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
| CN111410657B (zh) * | 2019-01-08 | 2024-05-21 | 北京鼎材科技有限公司 | 一种发光材料及其应用 |
| WO2025160629A1 (en) * | 2024-01-31 | 2025-08-07 | Certa Therapeutics Pty Ltd | Proton sensing gpcr modulators |
| US20250276984A1 (en) * | 2024-02-20 | 2025-09-04 | Iambic Therapeutics, Inc. | Solid state forms of her2 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
-
2014
- 2014-05-19 PL PL408251A patent/PL408251A1/pl unknown
-
2015
- 2015-05-14 EP EP15730261.3A patent/EP3145930B1/en active Active
- 2015-05-14 PT PT15730261T patent/PT3145930T/pt unknown
- 2015-05-14 CA CA2946258A patent/CA2946258C/en active Active
- 2015-05-14 ES ES15730261.3T patent/ES2688084T3/es active Active
- 2015-05-14 AU AU2015263013A patent/AU2015263013B2/en active Active
- 2015-05-14 EA EA201692264A patent/EA030330B9/ru not_active IP Right Cessation
- 2015-05-14 KR KR1020167035389A patent/KR102404650B1/ko active Active
- 2015-05-14 DK DK15730261.3T patent/DK3145930T3/en active
- 2015-05-14 CN CN201580025963.XA patent/CN106459060B/zh active Active
- 2015-05-14 US US15/311,698 patent/US10138245B2/en active Active
- 2015-05-14 HR HRP20181027TT patent/HRP20181027T1/hr unknown
- 2015-05-14 MX MX2016015180A patent/MX367647B/es active IP Right Grant
- 2015-05-14 JP JP2016568435A patent/JP6455947B2/ja active Active
- 2015-05-14 HU HUE15730261A patent/HUE039847T2/hu unknown
- 2015-05-14 SI SI201530382T patent/SI3145930T1/sl unknown
- 2015-05-14 WO PCT/IB2015/053549 patent/WO2015177688A1/en not_active Ceased
- 2015-05-14 PL PL15730261T patent/PL3145930T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2946258C (en) | 2023-06-06 |
| MX367647B (es) | 2019-08-29 |
| EA030330B1 (ru) | 2018-07-31 |
| EP3145930B1 (en) | 2018-07-04 |
| JP2017521364A (ja) | 2017-08-03 |
| US10138245B2 (en) | 2018-11-27 |
| CA2946258A1 (en) | 2015-11-26 |
| PL3145930T3 (pl) | 2018-11-30 |
| US20170114064A1 (en) | 2017-04-27 |
| KR20170005860A (ko) | 2017-01-16 |
| DK3145930T3 (en) | 2018-09-24 |
| CN106459060A (zh) | 2017-02-22 |
| KR102404650B1 (ko) | 2022-06-02 |
| JP6455947B2 (ja) | 2019-01-23 |
| HUE039847T2 (hu) | 2019-02-28 |
| MX2016015180A (es) | 2017-03-23 |
| WO2015177688A1 (en) | 2015-11-26 |
| ES2688084T3 (es) | 2018-10-30 |
| AU2015263013B2 (en) | 2018-10-04 |
| PT3145930T (pt) | 2018-10-11 |
| EA030330B9 (ru) | 2018-09-28 |
| HRP20181027T1 (hr) | 2018-08-24 |
| AU2015263013A1 (en) | 2016-11-17 |
| CN106459060B (zh) | 2019-04-05 |
| EA201692264A1 (ru) | 2017-04-28 |
| EP3145930A1 (en) | 2017-03-29 |
| SI3145930T1 (sl) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL408251A1 (pl) | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A | |
| CU24572B1 (es) | Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas | |
| SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MA40301B1 (fr) | Composés indolecarboxamides utiles comme inhibiteurs de kinase | |
| PH12017501586A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| PH12013501197B1 (en) | Indeno-fused ring compounds | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
| SG10201900144TA (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| MX373700B (es) | Composicion acuosa novedosa. | |
| MA50418A (fr) | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| EP2602254A4 (en) | HETEROCYCLIC CONNECTION | |
| BR112014004267A2 (pt) | derivado de ácido pirrolidina-3-ilacético | |
| MX2021007511A (es) | Procedimiento para la preparacion de anilinas sustituidas. | |
| WO2014184272A3 (en) | Chemical compositions for targeting isocitrate dehydrogenase and for treating cancer | |
| MX377854B (es) | Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona |